Dow Up, Edesa Biotech Up

All three major indices rose today.

The NASDAQ rose 236.41 points.

The DOW rose 370.44 points.

The S&P rose 53.32 points.

The Dow Jones Industrial Average closed higher amid rebounding sentiment as investors rotated back into tech and cyclicals following recent volatility, with positive economic data and easing concerns over AI disruption supporting gains. The blue-chip index added 370.44 points, or 0.8%, to finish at 49,174.50. This marked a solid advance in a session that helped recover from prior pressures, contributing to positive closes across the major benchmarks.

All this as Edesa Biotech shares rose 0.51 points to end the day at $1.51 per share. The clinical-stage biopharmaceutical company focused on host-directed therapeutics for immuno-inflammatory diseases stock surged dramatically after announcing additional positive results from its Phase 3 study of paridiprubart (EB05) for Acute Respiratory Distress Syndrome (ARDS) and related conditions. The data, from a 278-patient population, showed a statistically significant reduction in adjusted 28-day mortality to 24% from 33% placebo--a 27% relative reduction (p<0.001)--with consistent benefits across severity levels, comorbidities, and subgroups like non-ventilated patients (35% relative reduction in that exploratory cohort).

The stock opened at $1.00 and traded in a highly volatile range during the session, hitting a high of $1.78 and a low of $0.91, with trading volume exploding to approximately 97,982,800 shares--far exceeding typical daily averages for the micro-cap biotech. The gain represented a 67.96% increase from the previous close, driven by enthusiasm over the mortality-cutting data, potential for upcoming conference presentations (including an oral session at ATS 2026), and exploratory signals in pneumonia, sepsis, and acute kidney injury subgroups.

The outsized performance made Edesa Biotech one of the market's top gainers on a day when broader indices advanced due to sector rebounds and stabilizing sentiment. Investors reacted strongly to the reinforced efficacy profile and safety data (comparable to placebo), viewing it as a major step forward for the anti-TLR4 antibody in critical care settings.